Table 3 Tumor, patient, and treatment-related characteristics of patients undergoing neoadjuvant treatment without surgery per time cohort. IQR interquartile range, AC adenocarcinoma, SCC squamous cell carcinoma, nCRT neoadjuvant chemoradiotherapy, nCT neoadjuvant chemotherapy
| Â | Â | Before 2011 | From 2011 | All | Â |
|---|---|---|---|---|---|
Patients | n (%) | 62 (54.4) | 52 (45.6) | 114 | Â |
Gender |  |  |  |  | p = 0.342 |
 Male | n (%) | 47 (75.8) | 42 (80.8) | 89 | |
 Female | n (%) | 15 (24.2) | 10 (19.2) | 25 | |
Age | Median (IQR) Mean (range) | 65 (58–74) 64 (35–84) | 68 (61–74) 67 (32–86) | 67 (60–74) 65 (32–86) | p = 0.224 |
Histology |  |  |  |  | p = 0.077 |
 AC | n (%) | 24 (38.7) | 28 (53.8) | 52 | |
 SCC | n (%) | 38 (61.3) | 24 (46.2) | 62 | |
Clinical stage |  |  |  |  | p = 0.131 |
 cT2 | n (%) | 4 (6.5) | 3 (5.8) | 7 | |
 cT3 | n (%) | 45 (72.6) | 42 (80.8) | 87 | |
 cT3–4 | n (%) | 7 (11.3) | 7 (13.5) | 14 | |
 cT4 | n (%) | 6 (9.7) | 0 (0.0) | 6 | |
cN status |  |  |  |  | p = 0.173 |
 cN negative | n (%) | 4 (6.5) | 7 (13.5) | 11 | |
 cN positive | n (%) | 58 (93.5) | 45 (86.5) | 103 | |
Treatment type |  |  |  |  | p = 0.513 |
 nCRT | n (%) | 51 (82.3) | 42 (80.8) | 93 | |
 nCT | n (%) | 11 (17.7) | 10 (19.2) | 21 |